Pregabalin Capsule
Product Images NDC 80425-0025

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 80425-0025). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig 1

A line graph depicting percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin in doses of 25 mg, 100 mg, and 200 mg taken three times a day, alongside a placebo control, showing relative improvements in pain relief.*

FDA Label Image

Fig 10

A survival curve chart comparing Pregabalin and placebo over 180 days. The y-axis shows the estimated percentage of subjects without LTR (loss to response) and the x-axis shows days. Solid line represents Pregabalin, and dashed line represents placebo, illustrating differences in subject outcomes over time.*

FDA Label Image

Fig 11

A line graph depicting the percent of subjects improved versus the percent improved from baseline to Week 12 BOCF for Pregabalin compared to Placebo. The graph shows two curves, one solid line for Pregabalin and one dotted line for Placebo, indicating differences in subject improvement over various improvement percentages.*

FDA Label Image

Fig 12

A line graph comparing the percent of subjects improved from baseline to Week 16 using BOCF method for Pregabalin and placebo. The x-axis represents percent improvement from baseline to Week 16, while the y-axis shows the percent of subjects improved. Two lines represent Pregabalin and placebo data respectively, indicating a higher improvement rate for Pregabalin compared to placebo.*

FDA Label Image

Fig 2

A line graph comparing percent improvement in pain from baseline on the x-axis with percent of patients improved on the y-axis for two groups: Pregabalin 100 mg three times a day and placebo. The graph shows higher patient improvement rates for Pregabalin across different pain improvement percentages.*

FDA Label Image

Fig 3

A line graph depicting the percent improvement in pain from baseline over time for patients taking Pregabalin at different doses (75 mg, 150 mg, and 300 mg twice daily) compared to a placebo group. The graph shows the percent of patients improved on the vertical axis and time on the horizontal axis, illustrating pain improvement trends for each group.*

FDA Label Image

Fig 4

A line chart comparing the percent of patients improved with Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percent of patients improved. The chart illustrates higher improvement rates for Pregabalin dosages compared to placebo across varying improvement levels.*

FDA Label Image

Fig 5

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and a placebo group, showing trends in patient improvement over the range of pain improvement percentages.*

FDA Label Image

Fig 6

A bar graph depicting responder rates (%) from two studies, E1 and E3, comparing placebo and various doses of Pregabalin (50 mg/day, 150 mg/day, 300 mg/day, 600 mg/day) administered BID or TID. The graph shows higher responder rates with increased doses of Pregabalin compared to placebo, with statistical significance indicated for several doses.*

FDA Label Image

Fig 7

A line graph showing median percent change from baseline in seizure reduction versus pregabalin dose in mg/day. The graph compares four study groups with different dosing regimens: Study E1 BID, Study E2 TID, Study E3 BID, and Study E3 TID. Data points indicate increased seizure reduction with higher doses, with statistical significance noted by p-values ≤ 0.0001 at several doses. Placebo is represented as zero dose.*

FDA Label Image

Fig 9

A line graph comparing percent of patients improved by percent improvement in pain from baseline for Pregabalin at 300 mg, 450 mg, and 600 mg daily doses and placebo. The vertical axis shows the percent of patients improved, and the horizontal axis shows percent improvement in pain from baseline.*

FDA Label Image

Formula

An illustration showing the formula for calculating creatinine clearance (CLCr), which includes age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplication factor of 0.85 for female patients.*

FDA Label Image

Pregabalin 50 mg Cap Qty 30 80425 0025

Pregabalin 50 mg capsules, bottle label with 30 capsules, from Advanced Rx of Tennessee, LLC. The label includes the product NDC (80425-0025-03), lot number, expiration date, and storage instructions (20°-25°C). The label references a comparison to LYRICA and includes a caution about federal law restricting transfer to the prescribed patient only.*

FDA Label Image

Pregabalin 50 mg Cap Qty 60 80425 0025

Packaging label for Pregabalin 50 mg oral capsules, bottle count 60, manufactured by Advanced Rx of Tennessee, LLC. The label references product NDC 80425-0025-01 and source NDC 69238-1311-09, with lot number and expiration date information, and storage instructions to keep at 20°-25°C (68°-77°F).*

FDA Label Image

Pregabalin 50 mg Cap Qty 90 80425 0025

Label for Pregabalin 50 mg oral capsules by Advanced Rx of Tennessee, LLC, with product NDC 80425-0025-02. The label includes the lot number, expiration date, and storage instructions between 20°-25°C (68°-77°F). It references comparison to LYRICA and displays barcodes and the labeler's location in Nashville, TN.*

FDA Label Image

Structure

Chemical structure diagram of Pregabalin, showing its molecular components including an amino group, carboxyl group, and hydrocarbon backbone, consistent with the active ingredient Pregabalin in the product.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.